EMA recommends first EU treatment for spinal muscular atrophy

The European Medicines Agency (EMA), which evaluates medicinal products for use in EU, has recommended nusinersen (Spinraza; Biogen) as a treatment for patients with spinal muscular atrophy (SMA).
To read the whole article click on the headline